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Abstract: Recent approvals of siRNA-based products motivated the scientific community to explore
siRNA as a treatment option for several intractable ailments, especially cancer. The success of
approved siRNA therapy requires a suitable and safer drug delivery agent. Herein, we report a series
of oleyl conjugated histidine–arginine peptides as a promising nonviral siRNA delivery tool. The
conjugated peptides were found to bind with the siRNA at N/P ratio ≥ 2 and demonstrated complete
protection for the siRNA from early enzymatic degradation at N/P ratio ≥ 20. Oleyl-conjugated
peptide -siRNA complexes were found to be noncytotoxic in breast cancer cells (MCF-7 and MDAMB-231) and normal breast epithelial cells (MCF 10A) at N/P ratio of ~40. The oleyl-R3 -(HR)4 and
oleyl-R4 -(HR)4 showed ~80-fold increased cellular uptake in MDA-MB-231 cells at N/P 40. Moreover,
the conjugated peptides-siRNA complexes form nanocomplexes (~115 nm in size) and have an
appropriate surface charge to interact with the cell membrane and cause cellular internalization.
Furthermore, this study provides a proof-of-concept that oleyl-R5 -(HR)4 can efficiently silence STAT-3
gene (~80% inhibition) in MDA-MB-231 cells with similar effectiveness to Lipofectamine. Further
exploration of this approach holds a great promise in discovering a successful in vivo siRNA delivery
agent with a favorable pharmacokinetic profile.
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1. Introduction

Publisher’s Note: MDPI stays neutral

In 1998, Andrew Fire and Craig Mellow published a seminal paper in which they
discovered the phenomenon of post-transcriptional gene silencing (PTGS) and termed
it as RNA interference (RNAi) [1]. Later, in 2001, two research groups reported that
21 to 22 nucleotide (nt) double-stranded RNAs, popularly known as small interfering
RNAs (siRNAs), can induce gene silencing in mammalian cells without causing nonspecific
interferon response [2,3]. These siRNAs later kicked off a revolution in biology due to their
potential to inhibit virtually all genes by a base sequence alone, which gives RNAi several
advantages over small-molecule drugs as a therapeutic strategy [4]. Approval of the first
siRNA-based drug Patisiran (OnpattroTM ) by the U.S. Food and Drug Administration (FDA)
in 2018, followed by approvals of Givosiran (GivlaariTM ), and lumasiran (OXLUMOTM )
has fostered a renewed interest in siRNA-based therapeutics [4].
However, there are several extracellular as well as intracellular challenges related to the
effectiveness of siRNA therapy, which include its membrane impermeability degradation by
endonucleases and RNAases, clearance of siRNA delivery system by the reticuloendothelial
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system, endosomal entrapment and off-target RNAi activity [5]. Several delivery systems
and transfection agents have been investigated to address these challenges. For example,
lipofectamine [6], polyethyl imine (PEI) [7], a dynamic polyconjugate system (DPC) [8],
magnetic and metallic nanoparticles [6], viral carriers [9], dendrimers [10,11], and liposomebased approaches [12,13] have been studied extensively for intracellular delivery of siRNA.
Most of these delivery systems have their advantages as well as limitations [14–17]. The
approved siRNA products employed solid lipid nanoparticles as delivery vectors [18], and
these showed adequate safety in both in vitro and in vivo studies; nevertheless, there are
reports that raise concern for their long-term use [19,20]. Therefore, there is a critical need
to develop non-toxic and more efficient siRNA delivery tools.
Over the past two decades, it has been found that cell-penetrating peptides (CPPs) have
shown enhanced uptake and delivery of siRNA in the cells [21–23]. Tat or polyargininecontaining peptides were among key CPPs that have been used extensively in cargo delivery,
including siRNA delivery, due to the presence of multiple positively charged guanidinium
groups [24–26]. We have reported an alternate combination of histidine and arginine
amino acid (HR)4 as a molecular transporter of small molecule and phosphopeptide [27].
Recent studies demonstrated the use of histidine or arginine-containing CPPs to transport
siRNA [28,29]. Furthermore, the combination of arginine with histidine residues was
reported to modulate the cytotoxicity of the siRNA delivery system [30,31].
Fatty acylation has been reported to increase cellular uptake of CPPs with low cytotoxicity and enhanced siRNA transfection efficiency [27,29,32]. Alshamsan et al. reported that
hydrophobically modified PEI by oleic acid and stearic acid increased siRNA condensation,
protection of siRNA from FBS degradation, and cellular uptake of siRNA as compared to
the parent PEI [33]. It has also been reported that the N-terminal stearylation of argininerich peptides increased the transfection efficacy because hydrophobic moiety contributes
to the absorption of the complex on the membranes [34]. Similarly, Sharma et al. demonstrated that the oleyl-conjugated CGKRK peptide showed the highest efficiency in siRNA
uptake and silencing of kinesin spindle protein (KSP) compared to other saturated fatty acid
conjugated peptides [35]. Therefore, herein, we sought to extend oleic acid conjugation to
histidine–arginine-based peptides to develop an efficient and safer siRNA delivery system.
We hypothesized that conjugation of oleic acid to histidine and arginine residues (HR)4
would result in an amphiphilic molecule with optimal cationic charge and hydrophobic
bulk required for the efficient siRNA delivery. Net cationic charge/hydrophobic bulk ratio
dictates the selective membrane permeabilizing ability of the CPPs. The cationic charge will
be increased by the addition of arginine (R) residue between hydrophobic oleyl and cationic
(HR)4 residues. Moreover, increasing the hydrophobicity of the siRNA delivery system
using unsaturated oleic acid has been shown to enhance cellular uptake [36]. Therefore, to
identify the optimum charge/hydrophobic bulk ratio in our unique amphiphilic delivery
system, a series of fatty acylated peptides was designed by incorporating an increasing
number of R residues, i.e., C18* -(R)n -(HR)4 , (where C18* represents oleyl group and n = 0, 1,
2, 3, 4 or 5).
To the best of our knowledge, limited studies have reported the use of HR peptidebased carriers for siRNA delivery in triple-negative breast cancer cells (TNBC) [31]. However, the role of varying R residues in improving the cellular uptake of siRNA and modulation of the cytotoxicity of the peptide has not yet been performed. In this study, we
combined hydrophobicity enhancing motif (oleic acid), cationic peptide (HR)4 , and varying
R residues to develop an efficient siRNA delivery system for TNBC cell lines and evaluate
the silencing of model protein signal transducer and activator of transcription -3 (STAT-3).
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2. Materials and Methods
The protected building block amino acids (arginine and histidine) and arginine
preloaded on 2-chlorotrityl resin were purchased from Chem Impex Inc. (Bensenville, IL,
USA). 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
was purchased from Acrotein ChemBio Inc. (Hoover, AL, USA). N, N-diisopropylethylamine
(DIPEA) and all other reagents and chemicals for peptide synthesis were obtained from
Millipore Sigma (Milwaukee, WI, USA). Silencer® Negative Control #1 siRNA, Catalog #:
AM4635-AM4636 was purchased from Ambian Inc. (Austin, TX, USA). Negative control
siRNA, also called scrambled siRNA, was the siRNA with 24 nucleotide sequences and does
not target any gene product. The negative control siRNA was used to make siRNA-Peptide
conjugate complexes in order to perform binding affinity, serum stability, cytotoxicity assay,
and dynamic light scattering (DLS) experiments. Alexa Fluor 488 labeled nonsilencing
control siRNA with the sequence 50 -AAT TCT CCG AAC GTG TCA CGT-30 was purchased
from QIAGEN Sciences (Germantown, MD, USA). Alexa-488 labeled nonsilencing control
siRNA was used to perform cellular uptake studies using flow cytometry and confocal
microscopy. Hs_STAT3_7 FlexiTube siRNA was purchased from QIAGEN LLC (Germantown, Maryland, USA). The target sequence was 50-CAGCCTCTCTGCAGAATTCAA-30,
the sense strand was 50-GCUUCUCUGCAGAAUUCAATT-30 and the antisense strand
was 50-UUGAAUUCUGCAGAGAGGCTG-30. STAT-3 (124H6) Mouse mAb #9139 and
GAPDH (D4C6R) Mouse mAb #97166 were purchased from Cell Signaling Technology
(CST), (Danvers, MA, USA), for the Western blotting experiment. Horseradish peroxidase
(HRP)-linked secondary antibody was purchased from Abcam Inc. (Waltham, MA, USA).
Mini-PROTEAN TGX stain-free precast gels and Trans-Blot Turbo Mini 0.2 m PVDF transfer
packs #1704156 were purchased from Bio-Rad Inc. (Hercules, CA, USA). All other reagents
used for Western blotting experiments were purchased from Bio-Rad Inc (Hercules, CA, USA).
2.1. Synthesis and Purification of Oleyl Conjugated Peptides
The oleic acid conjugated peptides were synthesized using Fmoc/tBu solid-phase synthesis, as depicted by the representative example in Scheme 1 using previously published
reports [27,35]. Briefly, the preloaded NH2 -Arg(Pbf)-2-chlorotrityl resin as solid support
(0.30 mmol scale) was used to assemble peptide containing an alternate arginine and histidine residue as per the sequence of peptides, followed by N-terminal acylation with oleic
acid using 2-(1h-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/N,
N-diisopropylethylamine (HBTU/DIPEA). Finally, all the peptide conjugates were cleaved
using a freshly prepared cleavage cocktail reagent R (trifluoroacetic acid (TFA): thioanisole:
anisole: 1,2-ethanediol (EDT); 92:5:2:3; v/v/v/v) for 4 h, and peptides were precipitated using
cold diethyl ether, centrifuged and purified using reverse-phase high-performance liquid
chromatography (RP-HPLC) (Shimadzu, LC-20AP Prominence) with a gradient system
of water (H2 O), acetonitrile (CH3 CN) in 0.1%TFA (v/v) (5−90%, 50 min) on a reversedphase preparative column (00G-4436-P0-AX, Gemini Prep C18, 10 µm particle size). The
fractions were collected and analyzed using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometer (GT 0264, Bruker, Inc. Billerica, MA, USA).
Fractions showing a mass of expected compounds were pooled and lyophilized to obtain a
solid powder of peptides. Analytical HPLC was performed to further confirm the purity of
the compounds ≥ 95%, which were used in the biological assays. The chemical structures,
MALDI mass spectra and purity data of the compounds are shown in the Supplementary
Information. Table 1 represents the sequences of the peptide conjugates and their MALDI
mass characterization data.
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Oleyl-(HR)
Oleyl-(HR)44-OH
-OH
Oleyl-R-(HR)4-OH
Oleyl-R-(HR)4 -OH
Oleyl-RR-(HR)4-OH
Oleyl-RR-(HR)4 -OH
Oleyl-RRR-(HR)4-OH
Oleyl-RRR-(HR) -OH
Oleyl-RRRR-(HR)4 4-OH
Oleyl-RRRR-(HR)4 -OH
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Chemical
Formula
Chemical Formula
C
66H110N28O10
C66 H110 N28 O10
C72H122N32O11
C72 H122 N32 O11
C78H134N36O12
C78 H134 N36 O12
C84H146N40O13
C84 H146 N40 O13
C90H158N44O14
CC9096H
N 49O
H158
171N44
O14
14

Exact
Exact Mass
Mass
1454.896
1454.896
1610.997
1610.997
1767.098
1767.098
1923.199
1923.199
2079.300
2079.300
2234.417

Found
Found (M/Z)
(M/Z)
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[M
H]++
1455.996 [M ++ H]
1612.230 [M + 2 H]++
1612.230 [M + 2 H]
1767.642 [M]++
1767.642 [M]
1925.019 [M + 2 H]+
1925.019 [M + 2 H]+
2080.422 [M + H]+
+
2080.422[M
[M++2H]
2236.281
H]+

Oleyl-R5 -(HR)4

Oleyl-RRRRR-(HR)4 -OH

C96 H171 N49 O14

2234.417

2236.281 [M + 2 H]+
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2.3. Cell Culture
2.3. Cell Culture
HTB-26), breast adTriple-negative breast cancer cell line MDA-MB-231 (ATCC® No.
Triple-negative breast cancer cell line MDA-MB-231 (ATCC® No. HTB-26), breast
enocarcinoma MCF-7 cells (ATCC® ®No. HTB-22) and normal breast cells MCF-10A
adenocarcinoma MCF-7 cells (ATCC No. HTB-22) and normal breast cells MCF-10A
(ATCC® No. CRL10317) were purchased from American Type Culture Collection (ATCC)
(ATCC® No. CRL10317) were purchased from American Type Culture Collection (ATCC)
(Manassas, VA, USA). DMEM media, supplemented with fetal bovine serum (FBS, 10%)
(Manassas, VA, USA). DMEM media, supplemented with fetal bovine serum (FBS, 10%)
and penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin
and penicillin-streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in
in 0.9% NaCl, 1%), were used for the proliferation of MDA-MB-231 and MCF-7 cells.
0.9% NaCl, 1%), were used for the proliferation of MDA-MB-231 and MCF-7 cells. MEGM
MEGM
Kit #(catalog
CC-3150)
was from
purchased
from Lonza
Group Ltd. (MuenchenKit (catalog
CC-3150)# was
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Lonza Group
Ltd. (Muenchensteinerstrasse
38,
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38,
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the
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theThe
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line.
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MEGM
Supplement
pack
of MEBM
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Medium
(CC-3151)
andMedium
MEGM Supplement
pack
(CC-4136)
containing
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(CC-4136)
an orange
cap vial
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bovine
pituitary
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green cap
orange capcontaining
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pituitary
extract
(BPE),
green
cap vialextract
with human
vial with human epidermal growth factor (hEGF), Lilac cap vial with insulin, natural cap
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growth factor (hEGF), Lilac cap vial with insulin, natural cap vial with hydrocortisone, and
red cap vial with gentamicin sulfate-amphotericin (GA-1000). All the cell lines used in this
study were incubated in a humidified atmosphere of 5% CO2 and 95% air at 37 ◦ C. The
cells were handled under sterile conditions in Herasafe™ 2030i Class 2 A2 Biological Safety
Cabinets purchased from Thermo Scientific™ (Hanover Park, IL, USA). All supplies for the
cell culture experiments were obtained from Thermo Fisher Scientific.
2.4. In Vitro Cytotoxicity Assay
The in vitro cytotoxicity of the synthesized oleyl-conjugated peptides complexed with
scrambled siRNA at different N/P ratios ranging from 10 to 100 was determined in the
MDA-MB-231, MCF-7, and MCF-10A cell lines. The peptide-siRNA complexes were made
according to the protocol described in Section 2.2. A total of 10,000 cells per 0.1 mL were
seeded in each well in a 96-well plate using a multichannel pipette and were allowed to
adhere to the bottom of the plate for 24 h in the incubator. After 24 h, the cells were inspected
for their health and confluency. Different concentrations of the freshly prepared peptidesiRNA complexes were added to each well in triplicate and incubated for 48 h at 37 ◦ C in a
humidified atmosphere of 5% CO2 . After 48 h, 20 µL of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent was added to
each well using a multichannel pipette. The 96-well plates were centrifuged at 1000 rpm
(RCF =96× g) for 1 min to ensure the settling of the MTS reagent, and after that, the plates
were incubated for an additional 3 h. SpectraMax M2 microplate spectrophotometer was
used to determine the absorbance at 490 nm. The percentage cell viability was calculated
using the following formula


Average OD values of samples treated with the compound
% cell viability =
× 100
Average OD values of no treatment
2.5. Dynamic Light Scattering
The peptide-siRNA complexes were characterized using the dynamic light scattering
(DLS) technique. Malvern Nano ZS Zetasizer (Westborough, MA, USA) was used to
determine the hydrodynamic diameter and surface charge of the complexes at 25 ◦ C. The
zeta potential of the complexes was determined at 40 V using disposable folded capillary
cells (DTS1070). The calibration of the instrument was performed by transfer standard
DTS 1235. The disposable cuvettes were used for determining the hydrodynamic diameter.
The N/P ratio 40 was selected for performing the dynamic light scattering experiment. At
this N/P ratio, the final concentration of siRNA in the complex was 50 nM whereas the
concentration of oleyl-(HR)4 was 24 µM, oleyl-R1 -(HR)4 was 19.20 µM, oleyl-R2 -(HR)4 was
16 µM, oleyl-R3 -(HR)4 was 13.71 µM, oleyl-R4 -(HR)4 was 12 µM, and oleyl-R5 -(HR)4 was
10.67 µM. The final volume of the complex used for performing zeta potential was 750 µL.
The measurements were performed in triplicate, where each measurement consisted of
20 runs. The zeta potential values were calculated using the Smoluchowski model. All the
results passed the quality standard of the instrument.
Particle size was also determined at N/P 40 with the same concentrations of siRNA
and oleyl conjugated peptides as described above. The experiments were performed in
triplicate on each sample with an automatic attenuator setting. The results were checked
with the quality standards of the instruments and were represented as mean ± SD of three
independent experiments.
2.6. Cellular Internalization of siRNA
The cellular uptake of siRNA complexed with oleyl conjugated peptides was evaluated
using flow cytometry (BD-FACSVerse; BD Biosciences, San Jose, CA, USA) in live cells.
Alexa fluor 488-labeled scrambled siRNA was used for making complexes with oleyl
conjugated peptides. The peptide-siRNA complexes were made at N/P 40; the final
concentration of siRNA in each complex was 50 nM. The study was performed on MDA-
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MB-231 according to the protocol described by Mandal et al. [37]. Briefly, approximately
500,000 cells were seeded in each well of the six-well plates and were allowed to settle
for 24 h. The cells were treated with the conjugate-siRNA complexes (N/P 40) and were
incubated in a humidified atmosphere of 5% CO2 and 95% air at 37 ◦ C for 24 h. After 24 h
of treatment, the cells were washed three times with HBBS and were trypsinized. The
suspended cells were centrifuged for 5 min at 1000 rpm (96× g) at 4 ◦ C, and the cells pellet
was washed with HBSS three times to remove any traces of the medium. Finally, the cells
were resuspended in PBS and analyzed by flow cytometer using Alexa-Fluor-488 channel to
quantify the mean fluorescence intensity. The mean fluorescent intensity in the treated cells
was calculated for each sample based on the calibration of the signal gated with nontreated
cells, serving as a negative control. Alexa-488 labeled scrambled siRNA served as a second
negative control, and lipofectamine-siRNA treated cells were used as a positive control.
2.7. Cellular Uptake Study Using Confocal Microscopy
Confocal microscopy was used to corroborate the data obtained from flow cytometry.
There have been reports for using fixed cells [35,38–40] or live cells [41] for imaging the
cellular uptake of siRNA. We adopted the protocol of Aliabadi et al. [38] to perform the
confocal microscopy. Briefly, approximately 400,000 MDA-MB-231 cells were seeded on
coverslips in 6-well plates and were allowed to settle for 24 h. After 24 h, the cells were
visualized under an ordinary microscope for their health and confluency. Peptide-siRNA
complexes at N/P ratio 40 were made containing a final concentration of 50 nM of siRNA,
and the cells were treated with these complexes. Nontreated cells served as negative
control while lipofectamine-siRNA complexes were used as a positive control. After 24 h of
treatment, the cells grown on coverslips were washed 3 times with HBSS and fixed with
3.7% formaldehyde solutions solution for 30 min at room temperature. The cell membranes
of the cells were stained with Texas Red (TR) Phalloidin (Invitrogen) (1:250 in HBSS), while
the nuclei of the cells were stained with 40 ,6-diamidino-2-phenylindole (DAPI). Nikon A1R
confocal microscope system was used to image the fixed cells at 60X objective and different
filters for Alexa-488 (FITC), DAPI, and TR.
2.8. Gel Shifting Assay
Gel electrophoresis was performed to determine the binding affinity of the oleyl
conjugated peptides with scrambled siRNA. The peptides mentioned in Table 1 were mixed
with siRNA at N/P ratios ranging from 0 to 40, where the final concentration of siRNA in the
complexes was 50 nM. In contrast, the peptide’s concentration increased with an increase
in the N/P ratio. The complexes were made in HBSS buffer and were placed at room
temperature for adequate complexation of the siRNA and the peptides. N/P ratio 0 served
as a negative control in which no peptide was present. One percent agarose gel was freshly
prepared and stained with 0.5 µg/mL ethidium bromide. A total of 5 µL of gel loading
dye, purple (6X) (catalogue #B7024, New England Biolabs) (Ipswich, MA, USA), was added
to each complex before loading into the wells. The gel electrophoresis was carried out at
70 V, 400 mA for 20 min in TAE buffer (2 M Tris base, 1 M glacial acetic acid, 0.5 M sodium
EDTA, pH 8.3). The ChemiDoc XRS+ system, based on CCD high-resolution (Bio-Rad
Imager), was used to visualize the gel, and the intensity of the bands (representing unbound
siRNA) was quantified using Image Lab™ software. The experiment was performed in
triplicate; the representative images of the gels are represented in the results sections of the
manuscript. Percent binding (%Binding) was calculated as 100% × [(control siRNA − free
siRNA)/control siRNA].
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2.9. Protection of siRNA against Enzymatic Degradation
Oleyl conjugated peptides were examined for their ability to protect the siRNA from
the harsh biological environment consisting of nucleases that rapidly degrade siRNA. For
this purpose, the peptide-siRNA complexes were prepared with N/P ratios ranging from
0 to 40, with a final siRNA concentration in these complexes as 100 nM. N/P ratio 0 served
as a positive control, representing 100% intact siRNA. HBSS was used as a negative control.
Each of the peptide-siRNA complexes of different N/P ratios was exposed to 25% (v/v) FBS
solution in HBSS, and the mixture was incubated at 37 ◦ C for 24 h. After 24 h, the heparin
competition assay was used to dissociate the peptide-siRNA complex and determine the
amount of intact siRNA after exposure to FBS. For this purpose, 5 µL of a 2:3 mixture (v/v)
of heparin (5% solution in normal saline) and ethylenediaminetetraacetic acid (0.5 mM) was
added to each complex and left for 10 min. A total of 5 µL of gel loading dye, purple (6X),
was added to each mixture, and the samples were analyzed using 1% ethidium bromide
gel electrophoresis run at 70 V, 400 mA for 20 min. The gels were visualized under UV
illumination, and the intensity of the bands was determined using Image Lab™ software.
Three independent experiments were performed for each oleyl conjugated peptide. The
representative gel images are shown in the results section of the manuscript.
2.10. Protein Silencing Effect of siRNA (Western Blot)
STAT-3 is an essential protein overexpressed in several cancer types, including breast
cancer [42]. The silencing effect of the STAT-3 siRNA delivered via oleyl conjugated peptides
was determined by checking the expression of STAT-3 in peptide-siRNA complex treated
cells. Expression of STAT-3 in nontreated cells served as a negative control, whereas the
commercially used transfection agent lipofectamine (20 µg/mL) complexed with STAT-3
siRNA (50 nM) served as the positive control. STAT-3 expression was evaluated by the
Western blotting experiment. Approximately 500,000 MDA-MB-231 cells were seeded in
T-25 flasks and incubated at 37 ◦ C under standard growth conditions. After 24 h, the
cells were treated with peptide-siRNA complexes at N/P 40 for 48 h. The final siRNA
concentration at this N/P was 50 nM. After 48 h of treatment, MDA-MB-231 cell lysates
were prepared according to the standard protocol using RIPA buffer; the cell lysates were
then incubated on ice for 1 h, during which the tubes were sonicated for 3 min after every
10 min. Following sonication for 1 h to ensure the complete lysis of cells, the tubes were
centrifuged for 15 min at 12,000 rpm (RCF = 13,870× g) at 4 ◦ C. The supernatant from
the centrifuged tubes was transferred to a fresh set of pre-cooled microtubes, and the
total protein concentration was determined using BSA assay. Briefly, 200 µL of working
reagent (50:1 A:B) was added to 25 µL of standard and unknown samples in triplicate
into a 96-well plate, and the sample was mixed on a plate shaker for 30 s. The plate was
then incubated at 37 ◦ C and 5% CO2 for 30 min. After half an hour of incubation, the
absorbance was measured at 562 nm using a Spectra MAX M5 microplate reader. The
protein in each treatment sample was quantified using the BSA standard curve. A total
of 15 µg of the protein was loaded per well in a 10% Mini-PROTEAN® TGX Stain-Free.
Protein gel electrophoresis was performed in buffer (0.192 M glycine, 25 mM Tris, 0.1%
SDS) for 30 min at 200 V. The gel was then transferred to Mini PVDF membrane (Catalog
no. 1704156) using Trans-Blot® Turbo (Bio-Rad, Hercules, CA, USA). The membrane was
blocked in BSA 5% for 3 h and then incubated at 4 ◦ C overnight with the primary antibody
(1:1000 in TBS-T). The membrane was then washed with TBS-T six times (5 min each time)
and was subsequently incubated with the secondary HRP-linked antibody (1:1000 in TBS-T)
for 1 h, followed by the washing steps. The detection of the bands was done by ECL Detect
Kit using a ChemiDoc imager (Bio-Rad, Hercules, CA, USA). The bands were quantified
using Image Lab™ software of ChemiDoc imager.
2.11. Statistical Analysis
Data obtained from the above-described experiments are shown as mean ± SD of three
independent experiments unless stated otherwise. Ordinary one-way analyses of variance
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(ANOVA) with multiple comparisons using Bartlett’s test were conducted to analyze flow
cytometry and Western blotting data. Paired Student’s t-test was performed for comparison
among two groups. p-value < 0.05 was considered to be statistically significant.
3. Results and Discussion
3.1. Synthesis and Characterization of the Oleyl-Conjugated Histidine-Arginine-Containing Peptide
CPPs are 5−40 amino-acid-long peptides known for their ability to internalize the
cargo into the cell, and they have been used for siRNA delivery [23,43]. Positively
charged amino acids, such as arginine and lysine, are required for complex formation
with siRNA [32]. It has been suggested that intracellular delivery could be optimized by
adjusting the number of arginines in the peptide [44]. For instance, Tanaka et al. reported
that stearoyl -CH2 R4 H2 C peptide conjugate could be an effective siRNA carrier to exercise
silencing effect in vitro and in vivo [30]. Moreover, Dutta et al. reported that arginine-based
CPPs with side-chain modification of two stearyl moieties exhibited significantly enhanced
cellular internalization of siRNA even with only six L-arginine residues. This study infers
that lipopeptides having Arg-Sar-Arg motif and two stearyl moieties exhibit higher siRNA
internalization efficacy than stearylated nona-arginine and can be exploited as a promising
drug delivery vehicle for intracellular delivery of biomacromolecules [45].
Several studies [7,16,17,23,27,45] have used histidine and arginine-based CPPs to improve their effectiveness in delivering the siRNA and increasing the transfection efficiency.
In oligoarginine-based siRNA transporters, adjacent Arg−Arg repulsion between two
consecutive arginine residues and proteolytic instability of transporters limit the stability of
peptide−cargo complexes [45,46]. The surface charge of nanocomplexes can affect cellular
uptake, cytotoxicity, tumor penetration, and therapeutic efficacy [47,48]. Additionally,
the internalization of peptide–cargo complexes by endocytic pathways and endosomal
entrapment prevents cytosolic delivery of siRNA [49,50]. Polyethyleneimine-containing
polymer or delivery vehicle having histidine residues exhibit proton sponge effect and
facilitate the release of encapsulated cargo to the cytosol [51]. MacLachlan and coworkers
have demonstrated that unsaturation in cationic lipids can affect fusogenicity and cellular
uptake of delivering nucleic-acid-based therapeutic molecules [52]. Moreover, the substitution by histidine in oligoarginine peptide has proven to improve the safety of the
peptide allowing the optimization of the peptide structure mainly by changing its binding
energy and the 3D-hydrophobic moment [53]. The designed library of oleyl conjugated HR
containing CPPs proved to be comparatively less toxic to stearyl nona-arginine CPP [45].
Another interesting finding that led us to formulate and design the library of the peptides
mentioned above is that adding histidine to an oligoarginine CPP decreases the toxicity
and improves the effectiveness of the peptide [53]. Few studies have been conducted lately
to discover the role of arginine residues in lipid-based siRNA transfection agent. Recently,
Konate et al. conducted a comprehensive study in which they designed novel amphipathic
cell-penetrating peptides, called WRAP, for siRNA transfection [54]. The current study is
designed on the same lines to discover the lipid modified amphiphilic CPPs for efficient
siRNA delivery.
Peptides in Table 1 were synthesized using Fmoc/tBu solid-phase peptide chemistry
as depicted in Scheme 1 with the representative synthesis of oleyl-(HR)4 peptide. All the
peptides were characterized by MALDI-TOF mass spectroscopy (Table 1) and purified
using RP-HPLC. The analytical HPLC showed a purity of ≥95%. The spectra of mass data,
as well as the purity data of the synthesized conjugates, are provided in the Supplementary
Information (Figures S1–S12).
3.2. Cytotoxicity
The cytotoxicity profile of the peptide-siRNA complexes was determined to find the
safe N/P ratio (quantity of the peptide/siRNA) for cellular uptake and gene silencing
studies. Therefore, two breast cancer cell lines, MDA-MB-231 and MCF-7, and one normal
breast epithelial cell line (MCF-10A) were used. The peptide-siRNA complexes were formed
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Table 3. Hydrodynamic diameter of oleyl-conjugated peptides/siRNA complexes.
Peptide-siRNA Complex at N/P 40.

Z-Ave (d.nm)

SD

PDI

SD

Oleyl-(HR)4

120.1

±1.3

0.213

±0.03

Oleyl-R1 -(HR)4

116.9

±2.5

0.201

±0.06

Oleyl-R2 -(HR)4

115.6

±1.6

0.217

±0.05

Oleyl-R3 -(HR)4

117

±1.8

0.229

±0.03

Oleyl-R4 -(HR)4

115.2

±2.3

0.237

±0.07

Oleyl-R5 -(HR)4

115.6

±2.1

0.213

±0.04

The polydispersity index (PDI) gives the physical stability of nanosuspensions and
should be as low as possible for the long-time stability of nanosuspensions. A PDI value of
0.1 to 0.25 shows a fairly narrow size distribution, and PDI value more than 0.5 indicates a
very broad distribution of the polydispersity index [56]. The PDI values of ~0.2 indicate less
aggregation of the complexes (Table 3). Previously, Tanaka et al. reported the particle size
of ~103 nm for stearyl conjugated-CH2 R4 H2 C/siRNA complex at N/P 20 [30]. Moreover,
Biswas et al. studied several linear and cyclic stearyl and linoleyl conjugated peptides
for siRNA delivery and found the size in a range of 100 to 120 nm [31]. Based on the
previously reported data and the results from this study, it is plausible to speculate that
fatty-acyl conjugated amphiphilic peptides form complexes with siRNA in a nano-range
that contributes to their ability to internalize siRNA inside the cells.
3.4. Cellular Internalization of Alexa Fluor Labeled siRNA Using Flow Cytometry
Cellular uptake of siRNA is a crucial step required for its ability to bind to siRNAinduced silencing complex (RISC) with subsequent degradation of mRNA of the desired
gene. Once inside the cell, the siRNA that presumably internalizes via endocytosis
along with the carrier, the endosome must release the siRNA to make it able to bind
to RISC [4]. Cellular uptake study of the oleyl-conjugated-siRNA complexes at N/P 40 was
performed on MDA-MB-231 cells using flow cytometry as described earlier in Section 2.6.
MDA-MB-231 cells are relatively more resistant to transfection than other breast cancer
cell types [28,57].
Alexa Flour-488 labeled siRNA is commonly used to determine siRNA’s cellular internalization using fluorescence-activated cell sorting (FACS) flow cytometry (Figure 3).
Nontreated cells (NT) and Alexa-488 siRNA treated cells were used as a negative control,
lipofectamine-siRNA was used as positive control. The results suggest that there was
nonsignificant difference in fluorescent intensity between nontreated cells and Alexa-488
treated cells (p = 0.639). Although, there was a slight increase in fluorescent intensity
between oleyl-(HR)4 and oleyl-R1 -(HR)4 (p = 0.0447). However, there was nonsignificant difference in intensity when compared with Alexa-488 treated cells (p = 0.9988 for
oleyl-(HR)4, and p = 0.0504 for oleyl-R1 -(HR)4 ). There was a significant increase in mean
fluorescent intensity and the siRNA uptake by the cells with successive increase in arginine
residues, with the maximum cellular uptake observed by oleyl-R5 -(HR)4. Moreover, a nonsignificant difference in cellular uptake of lipofectamine and oleyl-R5 -(HR)4 was observed,
which can be corroborated with the comparable silencing efficiency of both compounds.
Based on the cellular uptake results, we did not perform further assays on oleyl-(HR)4 and
oleyl-R1 -(HR)4 .
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Figure 6. Gel retardation assay of oleyl-conjugated peptides/siRNA complexes at N/P ratios ranging
from 0 to 80. The bars indicate the mean intensity of the bands, representing percent siRNA bound
to the peptides, quantified by Image Lab software. Error bars show the standard deviation (n = 3).
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The quantification of the bands was done by the Image Lab software that represented
the percent bound siRNA to the peptides. The decrease in band intensity represents that
the siRNA is bound with the oleyl conjugated peptide, and hence its movement was retarded in the gel. At N/P 0, indicating only the siRNA, all the siRNA showed up as a thick
band; however, with an increase in N/P ratio (increase in peptide concentrations in the
complexes), percent bound siRNA increased, showing ~100% bound siRNA at N/P 20 and
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above (Figure 6). The binding affinity of the oleyl conjugated peptides is probably due to
the presence of arginine residues in the peptides that made complexes with siRNA
through ionic interactions with negatively charged phosphates in the siRNA.

3.7. Serum Stability of Peptide-siRNA Complexes
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3.8. STAT-3 Silencing Using Oleyl Conjugated Peptides/siRNA Complexes in MDA-MB-231
Cells
STAT3 is an essential member of the STAT family, a latent transcription factor that
acts as an oncogene in several malignant diseases [58]. Several investigators reported that
STAT3 aberrant expression was significantly associated with the status of lymph node
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3.8. STAT-3 Silencing Using Oleyl Conjugated Peptides/siRNA Complexes in
MDA-MB-231 Cells
STAT3 is an essential member of the STAT family, a latent transcription factor that acts
as an oncogene in several malignant diseases [58]. Several investigators reported that STAT3
aberrant expression was significantly associated with the status of lymph node metastasis
in various malignant diseases [42,59–61]. Several STAT-3 siRNA delivery agents have been
investigated but failed to reach clinical trials because of the cytotoxicity issue [62–64]. Very few
studies have used a peptide-based delivery system for siRNA; therefore, we chose STAT-3 as a
target protein using the novel fatty acyl conjugated histidine–arginine-based cell-penetrating
peptide. We used the Western blotting technique to determine the expression of STAT-3 in
MDA-MB-231 cells according to the method described in Section 2.10. Nontreated cells were
used as a negative control, whereas the commercial transfection agent Lipofectamine 2000 was
used as a positive control. It is pertinent to mention here that we also used scrambled siRNA
treated cells as negative control and found no significant difference in STAT-3 expression
between nontreated and scrambled siRNA treated cells (data not shown). A similar pattern
was observed in flow cytometry and confocal microscopy assay, where we did not observe
any significant difference in cellular uptake between Alexa-488 siRNA treated cells and
nontreated cells. The lack of cellular uptake in case of free siRNA is attributed to its membrane
impermeability due to the presence of negatively charged phosphate groups. GAPDH protein
served as a housekeeping protein. The final siRNA concentration in each treatment group
was 50 nM. The peptide concentrations in the complexes are described in Table 4, which are
Pharmaceutics 2022, 14, x FOR PEER REVIEW
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way less than the cytotoxic concentrations as determined by the cytotoxicity assay described
in Section 3.2.
Table 4. Treatment concentrations of Peptides for Western blotting assay.
Table 4. Treatment concentrations of Peptides for Western blotting assay.
Compound

Compound

N/P Ratio

Oleyl-R -(HR)

2
4
Oleyl-R2-(HR)
4
Oleyl-R
3 -(HR)
4
Oleyl-R
3-(HR)
4
Oleyl-R
4 -(HR)
4
Oleyl-R
4-(HR)
4
Oleyl-R
Oleyl-R
5-(HR
)4
5 -(HR
)4

40
40
40
40

Final Concentration of Peptide
W/W Ratio
Final
Concentration
of Peptide in
N/P
Ratio
in the Complex (µM)
(Peptide/siRNA)
W/W Ratio (Peptide/siRNA)
40
40
40
40

the Complex (µM)
16
16
13.71
13.71
12
12
10.67
10.67

42.51

42.51
39.66 39.66
37.53 37.53
35.87 35.87

Molar Ratio
Molar
Ratio
(Peptide/siRNA)
(Peptide/siRNA)
320
320
274.29
274.29
240
240
213.33
213.33
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Figure 9. Western blot image of STAT-3 protein silencing in MDA-MB-231 cells. Where GAPDH served
as a house-keeping
protein;
= Nontreated
Lipo=inLipofectamine
A Where
= Oleyl-R
2 -(HR)4 ,
Figure
9. Western blot
image[NT
of STAT-3
proteinCells,
silencing
MDA-MB-2312000,
cells.
GAPDH
B = Oleyl-R
= Oleyl-R5 -(HR)
3 -(HR)4 , C = Oleyl-R
4 -(HR)
served
as a house-keeping
protein;
[NT4 ,=DNontreated
Cells,4 ].Lipo= Lipofectamine 2000, A = Oleyl-

R2-(HR)4, B = Oleyl-R3-(HR)4, C = Oleyl-R4-(HR)4, D = Oleyl-R5-(HR)4].

Furthermore, we quantified the Western blot data from three independent experiments
using
Image Lab software
presented
in Figureblot
10. The
a comparable
inhibiFurthermore,
we quantified
the Western
datadata
fromindicates
three independent
experition
of
STAT-3
expression
with
oleyl-R
-(HR)
to
that
of
lipofectamine.
Another
exciting
5 in Figure
4
ments using Image Lab software presented
10. The data indicates a comparable
trend is that increasing the number of arginine residues affects the delivery efficiency of the
inhibition of STAT-3 expression with oleyl-R5-(HR)4 to that of lipofectamine. Another exfatty acyl peptide conjugates which correlate with silencing of STAT-3 gene. For instance,
citing trend is that increasing the number of arginine residues affects the delivery effithere is a significant reduction in STAT-3 expression when the conjugates are compared
ciency of the fatty acyl peptide conjugates which correlate with silencing of STAT-3 gene.
For instance, there is a significant reduction in STAT-3 expression when the conjugates
are compared with each other with the maximum reduction observed with the conjugate
containing a total of nine arginine residues (oleyl-R5-(HR)4).
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with each other with the maximum reduction observed with the conjugate containing a
total of nine arginine residues (oleyl-R5 -(HR)4 ).

Figure 10. Normalized STAT-3 expression quantified from the Western blot after 48 h of treatment
Figurepeptides-siRNA
10. Normalized complexes
STAT-3 expression
quantified
the Western
after 48
with oleyl conjugated
at N/P 40.
ns meansfrom
nonsignificant,
***blot
indicates
a h of trea
with
oleyl
conjugated
peptides-siRNA
complexes
at
N/P
40.
ns
means
nonsignificant,
*** ind
p-value < 0.001, and **** indicate a p-value < 0.0001.
a p-value < 0.001, and **** indicate a p-value < 0.0001.
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the efficient delivery of siRNA with subsequent silencing of the target protein. Bes
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that oleyl-conjugated histidine arginine peptide can provide a promising strategy in the
efficient delivery of siRNA with subsequent silencing of the target protein. Besides, the
data from this research may provide a framework for determining the appropriate dose of
the peptide-siRNA complex that can be subsequently employed for formulating a dosage
form for in vivo studies to develop siRNA therapeutics. Exploration of fatty acyl histidine–
arginine-containing CPPs provides a promising approach to siRNA delivery.
Supplementary Materials: The following supporting information can be downloaded at: https:
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spectrometry spectrum (Figures S7–S12) and analytical HPLC chromatograms (Figures S1–S6).
Author Contributions: Conceptualization, R.K.T., M.I.S. and D.M.; Methodology and design of
Experiments, R.K.T., N.S.E.-S., D.M. and M.I.S.; Experiments, M.I.S.; Analysis and critical comments
of Data, D.M. and R.K.T.; Proof reading, D.M., N.S.E.-S. and R.K.T.; Confocal Microscopy Images,
J.M.; Synthesis and Purification of conjugates, M.I.S., N.S.E.-S. and S.L. All authors have read and
agreed to the published version of the manuscript.
Funding: This research was funded by Chapman University School of Pharmacy, Irvine, California,
and the Fulbright Commission for Pakistan administered by the United States Education Foundation
in Pakistan.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: We acknowledge the feedback of Keykavous Parang and Hamidreza Montazeri
Aliabadi.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.
6.
7.
8.

9.
10.

11.
12.

Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806–811. [CrossRef]
Caplen, N.J.; Parrish, S.; Imani, F.; Fire, A.; Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNAs in
invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 2001, 98, 9742–9747. [CrossRef]
Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA
interference in cultured mammalian cells. Nature 2001, 411, 494–498. [CrossRef]
Sajid, M.I.; Moazzam, M.; Kato, S.; Yeseom Cho, K.; Tiwari, R.K. Overcoming barriers for siRNA therapeutics: From bench to
bedside. Pharmaceuticals 2020, 13, 294. [CrossRef]
Subhan, M.A.; Torchilin, V. siRNA based drug design, quality, delivery and clinical translation. Nanomed. Nanotechnol. Biol. Med.
2020, 29, 102239. [CrossRef]
Park, J.W.; Bae, K.H.; Kim, C.; Park, T.G. Clustered magnetite nanocrystals cross-linked with PEI for efficient siRNA delivery.
Biomacromolecules 2011, 12, 457–465. [CrossRef]
Liu, G.; Xie, J.; Zhang, F.; Wang, Z.; Luo, K.; Zhu, L.; Quan, Q.; Niu, G.; Lee, S.; Ai, H. N-Alkyl-PEI-functionalized iron oxide
nanoclusters for efficient siRNA delivery. Small 2011, 7, 2742–2749. [CrossRef]
Rozema, D.B.; Lewis, D.L.; Wakefield, D.H.; Wong, S.C.; Klein, J.J.; Roesch, P.L.; Bertin, S.L.; Reppen, T.W.; Chu, Q.; Blokhin, A.V.
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 12982–12987.
[CrossRef]
Nedra Karunaratne, D.; Jafari, M.; Udayana Ranatunga, R.; Siriwardhana, A. Natural carriers for siRNA delivery. Curr. Pharm.
Des. 2015, 21, 4529–4540. [CrossRef]
Pan, J.; Mendes, L.P.; Yao, M.; Filipczak, N.; Garai, S.; Thakur, G.A.; Sarisozen, C.; Torchilin, V.P. Polyamidoamine dendrimersbased nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. Eur. J.
Pharm. Biopharm. 2019, 136, 18–28. [CrossRef]
Wu, J.; Huang, W.; He, Z. Dendrimers as carriers for siRNA delivery and gene silencing: A review. Sci. World J. 2013, 630654.
[CrossRef] [PubMed]
Jiang, J.; Yang, S.-j.; Wang, J.-c.; Yang, L.-j.; Xu, Z.-z.; Yang, T.; Liu, X.-y.; Zhang, Q. Sequential treatment of drug-resistant tumors
with RGD-modified liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 2010, 76, 170–178. [CrossRef] [PubMed]

Pharmaceutics 2022, 14, 881

13.

14.
15.
16.
17.
18.
19.
20.

21.
22.
23.
24.

25.
26.
27.
28.
29.

30.
31.

32.

33.
34.
35.
36.
37.
38.

20 of 21

Chien, P.-Y.; Wang, J.; Carbonaro, D.; Lei, S.; Miller, B.; Sheikh, S.; Ali, S.M.; Ahmad, M.U.; Ahmad, I. Novel cationic cardiolipin
analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 2005, 12, 321–328.
[CrossRef] [PubMed]
Schroeder, A.; Levins, C.G.; Cortez, C.; Langer, R.; Anderson, D.G. Lipid-based nanotherapeutics for siRNA delivery. J. Intern.
Med. 2010, 267, 9–21. [CrossRef] [PubMed]
Davis, M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From
concept to clinic. Mol. Pharm. 2009, 6, 659–668. [CrossRef]
Lächelt, U.; Wagner, E. Nucleic acid therapeutics using polyplexes: A journey of 50 years (and beyond). Chem. Rev. 2015, 115,
11043–11078. [CrossRef]
Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.; Stebbing, D.; Crosley, E.J.; Yaworski, E. Rational
design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28, 172–176. [CrossRef]
Suzuki, Y.; Ishihara, H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA
(COVID-19 vaccine) drugs. Drug Metab. Pharmacokinet. 2021, 41, 100424. [CrossRef]
Winter, E.; Pizzol, C.D.; Locatelli, C.; Crezkynski-Pasa, T.B. Development and evaluation of lipid nanoparticles for drug delivery:
Study of toxicity in vitro and in vivo. J. Nanosci. Nanotechnol. 2016, 16, 1321–1330. [CrossRef]
Fonseca-Gomes, J.; Loureiro, J.A.; Tanqueiro, S.R.; Mouro, F.M.; Ruivo, P.; Carvalho, T.; Sebastião, A.M.; Diógenes, M.J.; Pereira,
M.C. In vivo bio-distribution and toxicity evaluation of polymeric and lipid-based nanoparticles: A potential approach for chronic
diseases treatment. Int. J. Nanomed. 2020, 15, 8609. [CrossRef]
Raucher, D.; Ryu, J.S. Cell-penetrating peptides: Strategies for anticancer treatment. Trends Mol. Med. 2015, 21, 560–570. [CrossRef]
[PubMed]
Guidotti, G.; Brambilla, L.; Rossi, D. Cell-penetrating peptides: From basic research to clinics. Trends Pharmacol. Sci. 2017, 38, 406–424.
[CrossRef] [PubMed]
Lehto, T.; Ezzat, K.; Wood, M.J.; Andaloussi, S.E. Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 2016, 106, 172–182.
[CrossRef] [PubMed]
Moschos, S.A.; Jones, S.W.; Perry, M.M.; Williams, A.E.; Erjefalt, J.S.; Turner, J.J.; Barnes, P.J.; Sproat, B.S.; Gait, M.J.; Lindsay, M.A.
Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression
and induction of innate immunity. Bioconjug. Chem. 2007, 18, 1450–1459. [CrossRef]
Wang, Y.H.; Hou, Y.W.; Lee, H.J. An intracellular delivery method for siRNA by an arginine-rich peptide. J. Biochem. Biophys.
Methods 2007, 70, 579–586. [CrossRef]
Kim, S.W.; Kim, N.Y.; Choi, Y.B.; Park, S.H.; Yang, J.M.; Shin, S. RNA interference in vitro and in vivo using an arginine
peptide/siRNA complex system. J. Control. Release 2010, 143, 335–343. [CrossRef]
El-Sayed, N.S.; Miyake, T.; Shirazi, A.N.; Park, S.E.; Clark, J.; Buchholz, S.; Parang, K.; Tiwari, R. Design, synthesis, and evaluation
of homochiral peptides containing arginine and histidine as molecular transporters. Molecules 2018, 23, 1590. [CrossRef]
Mozaffari, S.; Bousoik, E.; Amirrad, F.; Lamboy, R.; Coyle, M.; Hall, R.; Alasmari, A.; Mahdipoor, P.; Parang, K.; Montazeri
Aliabadi, H. Amphiphilic peptides for efficient siRNA delivery. Polymers 2019, 11, 703. [CrossRef]
Freire, J.M.; de Figueiredo, I.R.; Valle, J.; Veiga, A.S.; Andreu, D.; Enguita, F.J.; Castanho, M.A. siRNA-cell-penetrating peptides
complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model. J. Control. Release 2017,
245, 127–136. [CrossRef]
Tanaka, K.; Kanazawa, T.; Ogawa, T.; Takashima, Y.; Fukuda, T.; Okada, H. Disulfide crosslinked stearoyl carrier peptides
containing arginine and histidine enhance siRNA uptake and gene silencing. Int. J. Pharm. 2010, 398, 219–224. [CrossRef]
Biswas, A.; Chakraborty, K.; Dutta, C.; Mukherjee, S.; Gayen, P.; Jan, S.; Mallick, A.M.; Bhattacharyya, D.; Sinha Roy, R. Engineered
histidine-enriched facial Lipopeptides for enhanced intracellular delivery of functional siRNA to triple negative breast Cancer
cells. ACS Appl. Mater. Interfaces 2019, 11, 4719–4736. [CrossRef] [PubMed]
Damen, M.; Aarbiou, J.; van Dongen, S.F.; Buijs-Offerman, R.M.; Spijkers, P.P.; van den Heuvel, M.; Kvashnina, K.; Nolte, R.J.;
Scholte, B.J.; Feiters, M.C. Delivery of DNA and siRNA by novel gemini-like amphiphilic peptides. J. Control. Release 2010, 145, 33–39.
[CrossRef] [PubMed]
Alshamsan, A.; Haddadi, A.; Incani, V.; Samuel, J.; Lavasanifar, A.; Uludag, H. Formulation and delivery of siRNA by oleic acid
and stearic acid modified polyethylenimine. Mol. Pharm. 2009, 6, 121–133. [CrossRef] [PubMed]
Futaki, S.; Ohashi, W.; Suzuki, T.; Niwa, M.; Tanaka, S.; Ueda, K.; Harashima, H.; Sugiura, Y. Stearylated arginine-rich peptides:
A new class of transfection systems. Bioconjugate Chem. 2001, 12, 1005–1011. [CrossRef]
Sharma, M.; El-Sayed, N.S.; Do, H.; Parang, K.; Tiwari, R.K.; Aliabadi, H.M. Tumor-targeted delivery of siRNA using fatty
acyl-CGKRK peptide conjugates. Sci. Rep. 2017, 7, 6093. [CrossRef]
Wang, X.; Yu, B.; Ren, W.; Mo, X.; Zhou, C.; He, H.; Jia, H.; Wang, L.; Jacob, S.T.; Lee, R.J. Enhanced hepatic delivery of siRNA and
microRNA using oleic acid based lipid nanoparticle formulations. J. Control. Release 2013, 172, 690–698. [CrossRef]
Mandal, D.; Mohammed, E.H.M.; Lohan, S.; Mandipoor, P.; Baradaran, D.; Tiwari, R.K.; Parang, K.; Aliabadi, H.M. RedoxResponsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery. Mol. Pharm. 2022. [CrossRef]
Aliabadi, H.M.; KC, R.B.; Bousoik, E.; Hall, R.; Barbarino, A.; Thapa, B.; Coyle, M.; Mahdipoor, P.; Uludağ, H. A systematic comparison
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